Condition (MeSH)
Polyploidy
ClinicalTrials.gov lists 1 trial for Polyploidy or a narrower condition beneath it. Igenomix has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
2 sections measured, none recorded · 1 not measured yet · 1 not computed
When did Polyploidy trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2025 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polyploidy trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 1 |
How many Polyploidy trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polyploidy trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Igenomix | 1 |
Which publications cover Polyploidy? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. | Communications biology | 2021 | Yes |
| Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. | The Journal of clinical investigation | 2015 | Yes |
| Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. | Blood | 2013 | Yes |
| Prolonged thrombocytopenia following allogeneic hematopoietic stem cell transplantation and its association with a reduction in ploidy and an immaturation of megakaryocytes. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation | 2011 | Yes |
| Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. | Cancer genetics and cytogenetics | 2006 | Yes |
Showing 5 of 17 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Polyploidy syndrome | 96321 | Exact | Orphadata Science knowledge files, Product 1 |
| Polyploidy syndrome | 96321 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and prevalence.
Not computed for conditions with fewer than 10 trials: drugs tested.